IP Library › Granted Patent US 9,981,942

Granted Patent B2

US 9,981,942 · App. 15/106,363 · Granted May 29, 2018

Piperidine derivatives having multimodal activity against pain

Inventors: Félix Cuevas-Cordobés (Valdemoro, ES); Carmen Almansa-Rosales (Barcelona, ES); Monica Garcia Lopez (Barcelona, ES)

Assignee: LABORATORIOS DEL DR. ESTEVE S.A.

C07D401/06 C07D401/14 C07D405/14 C07D413/06 C07D413/14 C07D417/14 C07D487/04

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,981,942
App. No.: 15/106,363
Granted: May 29, 2018
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to piperidene compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Claims (234)

1. A compound of general formula (I):

wherein

m is 1 or 2;

one of V 1 , V 2 and V 3 is nitrogen or carbon while the other two are carbon;

R 1 is hydroxyl, —NR 6 R 7 , —NR 6 S(O) 2 R 7 , —NR 6 COR 7 , —NR 6 CONR 7 R 8 , —SR 6 , —S(O) 2 R 6 , —S(O) 2 NR 6 R 7 , —CONR 6 R 7 , substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;

R 2 is hydrogen, halogen, —NR 6 R 7 , —SR 6 , —OR 6 , substituted or unsubstituted alkyl, substituted of unsubstituted saturated cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;

R 1 and R 2 are bonded to neighbouring atoms in the ring and together with these atoms form a saturated or unsaturated, substituted or unsubstituted ring, fused to

the ring

of the core structure of formula I, which may be condensed with a further unsubstituted or substituted ring system;

R 5 is hydrogen, halogen, hydroxy, substituted or unsubstituted O-alkyl, or substituted or unsubstituted alkyl;

R 6 , R 7 and R 8 are independent from each other and selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, or R 5 , R 7 or R 8 together with their respective connecting carbon or nitrogen atom may form a cycloalkylic or heterocyclic 4 to 7-membered ring;

and wherein W, X, Y and Z are selected from carbon, nitrogen, or oxygen while W—X—Y—Z together with the bridging C-atom, that is connected to the core scaffold, form a 5-membered heterocyclic ring, which is either substituted on one of W, X,

Y or Z by

or in which this 5-membered heterocyclic ring—being otherwise unsubstituted—is fused at W and X to a further ring system;

wherein

n is 0 or 1;

R 3 is substituted or unsubstituted alkyl, CONR 6 R 7 , substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;

R 4 is hydrogen, substituted or unsubstituted alkyl, substituted of unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted of unsubstituted aryl or substituted of unsubstituted heterocyclyl;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof, or a solvate thereof;

with the following provisos:

with the proviso that if V 1 , V 2 and V 3 are carbon and one of W, X, Y or Z is

wherein n is 0, then R 1 may not be —NHC(O)-alkyl in the meta position;

with the proviso that if V 1 is nitrogen while V 2 and V 3 are carbon and either X or Y is

wherein n=0 and R 3 is alkyl, then neither R 1 nor R 2 may be —NR 6 R 7 in the meta position and R 2 may not be —CH 3 in the meta position; and

with the proviso that if V 1 is nitrogen while V 2 and V 3 are carbon and either W or Z is

wherein n=0 and R 3 is alkyl, then R 2 may not be —NR 6 R 7 in the meta position.

2. A compound of Formula II:

wherein

m is 1 or 2;

n is 0 or 1;

one of V 1 , V 3 , V 4 and V 5 is nitrogen or carbon while the other three are carbon;

R 1 and R 2 are bonded to neighbouring atoms in the ring and together with these atoms form a saturated or unsaturated, substituted or unsubstituted ring, fused to the ring

of the core structure of formula II, which may be condensed with a further unsubstituted or substituted ring system;

R 4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted of unsubstituted aryl or substituted of unsubstituted heterocyclyl;

R 5 is hydrogen, halogen, hydroxy, substituted or unsubstituted O-alkyl, or substituted or unsubstituted alkyl;

R 6 , R 7 and R 8 are independent from each other and selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, or R 6 , R 7 or R 8 together with their respective connecting carbon or nitrogen atom form a cycloalkylic or heterocyclic 4 to 7-membered ring;

and wherein W, X, Y and Z are selected from carbon, nitrogen, and oxygen while W—X—Y—Z together with the bridging C-atom, that is connected to the core scaffold, form a 5-membered heterocyclic ring,

or wherein

with the following provisos:

with the proviso that if V 1 , V 3 , V 4 and V 6 are carbon and one of W, X, Y or Z is

wherein n is 0, then R 1 may not be —NHC(O)-alkyl;

with the proviso that if V 1 is nitrogen while V 3 , V 4 and V 6 are carbon and either X or Y is

wherein n=0 and R 3 is alkyl, then R 3 may not be —NR 6 R 7 .

3. A compound of Formula III:

wherein

m is 1 or 2;

n is 0 or 1;

V 1 is nitrogen or carbon;

R 2 is hydrogen, halogen, —NR 6 R 7 , —SR 6 , —OR 6 , substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;

R 1 and R 2 are bonded to neighbouring atoms in the ring and together with these atoms form a saturated or unsaturated, substituted or unsubstituted ring, fused to the ring

of the core structure of formula III, which may be condensed with a further unsubstituted or substituted ring system;

R 4 is hydrogen, substituted or unsubstituted alkyl, substituted of unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or substituted of unsubstituted heterocyclyl;

R 5 is hydrogen, halogen, hydroxy, substituted or unsubstituted O-alkyl, or substituted or unsubstituted alkyl;

R 6 , R 7 and R 8 are independent from each other and selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, or R 6 , R 7 or R 8 together with their respective connecting carbon or nitrogen atom form a cycloalkylic or heterocyclic 4 to 7-membered ring;

and

is:

with the following provisos:

with the proviso that if V 1 is nitrogen and

is,

wherein n=0 and R 3 is alkyl, then R 1 may not be —NR 6 R 7 ;

with the proviso that if V 1 is carbon and

or wherein n is 0, then R 1 may not be —NHC(O)-alkyl in the meta position.

4. The compound according to claim 3 , which is a compound of formula IV:

wherein

m is 1 or 2;

n is 0 or 1;

V 1 is carbon or nitrogen;

one of W, X and Y is carbon, while the other two are nitrogen;

R 1 is hydroxy, NR 6 R 7 , —NR 6 S(O) 2 R 7 , —NR 6 COR 7 , —NR 6 CONR 7 R 8 , —SR, —S(O) 2 R 5 , —S(O) 2 NR 6 R 7 , —CONR 6 R 7 , substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;

R 1 and R 2 are bonded to neighbouring atoms in the ring and together with these atoms form a saturated or unsaturated, substituted or unsubstituted ring, fused to

the ring

of the core structure of formula IV, which may be condensed with a further unsubstituted or substituted ring system;

R 5 is hydrogen, halogen, hydroxy, substituted or unsubstituted O-alkyl, or substituted or unsubstituted alkyl;

R 6 , R 7 and R 8 are independent from each other and selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, or R 6 , R 7 or R 8 together with their respective connecting carbon or nitrogen atom form a cycloalkylic or heterocyclic 4 to 7-membered ring;

5. The compound according to claim 3 , wherein

6. The compound according to claim 3 , wherein

7. The compound according to claim 3 , which is a compound of formula V:

wherein

m is 1 or 2;

n is 0 or 1;

V 1 is CH or N;

W is CH or O and Z is N or O, with a maximum of one of them being O;

R 1 is hydroxy, NR 6 R 7 , —NR 6 S(O) 2 R 7 , —NR 6 COR 7 , —NR 6 CONR 7 R 8 , —SR 6 , —S(O) 2 R 6 , —S(O) 2 NR 6 R 7 , —CONR 6 R 7 , substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;

R 1 and R 2 are bonded to neighbouring atoms in the ring and together with these atoms form a saturated or unsaturated, substituted or unsubstituted ring, fused to

the ring

of the core structure of formula V, which may be condensed with a further unsubstituted or substituted ring system;

R 3 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;

R 4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or substituted of unsubstituted heterocyclyl;

R 5 is hydrogen, halogen, hydroxy, substituted or unsubstituted O-alkyl, or substituted or unsubstituted alkyl;

R 6 , R 7 and R 8 are independent from each other and selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, or R 6 , R 7 or R 8 together with their respective connecting carbon or nitrogen atom form a cycloalkylic or heterocyclic 4 to 7-membered ring;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or a mixture of at least two of the stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof.

8. The compound according claim 3 , which is a compound of formula VI:

wherein

m is 1 or 2;

V 1 is nitrogen or carbon;

n is 0 or 1;

one of W and X is N or CH, while the other is

and

one of Y and Z is selected from N or CH, while the other is N, with only a maximum of 2 of W, X, Y or Z being N;

R 1 is hydroxy, NR 6 R 7 , —NR 6 S(O) 2 R 7 , —NR 6 COR 7 , —NR 6 CONR 7 R 8 , —SR 6 , —S(O) 2 R 6 , —S(O) 2 NR 6 R 7 , —CONR 6 R 7 , substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclyl;

R 1 and R 2 are bonded to neighbouring atoms in the ring and together with these atoms form a saturated or unsaturated, substituted or unsubstituted ring, fused to

the ring

of the core structure of formula VI, which may be condensed with a further unsubstituted or substituted ring system;

R 3 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;

R 5 is hydrogen, halogen, hydroxy, substituted or unsubstituted O-alkyl, or substituted or unsubstituted alkyl;

R 6 , R 7 and R 8 are independent from each other and selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, or R 6 , R 7 or R 8 together with their respective connecting carbon or nitrogen atom form a cycloalkylic or heterocyclic 4 to 7-membered ring;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof.

9. The compound according to claim 3 , wherein

the aryl is selected from phenyl, naphthyl, or anthracene;

the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring;

the aryl is phenyl, naphthyl or anthracene;

the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur

the alkyl is C 1-8 alkyl;

the alkenyl is C 2-10 -alkenyl;

the alkynyl is C 2-10 -alkynyl;

the cycloalkyl is C 3-8 cycloalkyl;

the halogen is fluorine, chlorine, iodine or bromine;

R 1 and R 2 are bonded to neighbouring atoms in the ring and together with these atoms form a saturated or unsaturated, substituted or unsubstituted ring, fused to

the ring

of the core structure of formula I, which may be condensed with a further unsubstituted or substituted ring system, wherein

the ring is either unsubstituted or substituted by one or more of halogen, —OH, —NH 2 , —SH, ═O, —OC 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen, —CN, or C 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen;

the aryl is phenyl, naphthyl or anthracene;

the alkyl is C 1-8 alkyl;

the alkenyl is C 2-10 -alkenyl;

the alkynyl is C 2-10 -alkynyl;

the cycloalkyl is C 3-8 cycloalkyl;

the aryl is phenyl, naphthyl or anthracene;

the alkyl is C 1-8 alkyl;

the alkenyl is C 2-10 -alkenyl;

the alkynyl is C 2-10 -alkynyl;

the cycloalkyl is C 3-8 cycloalkyl;

R 5 is hydrogen, halogen, hydroxy, substituted or unsubstituted O-alkyl, substituted or unsubstituted alkyl, wherein

the alkyl is C 1-8 alkyl;

the O-alkyl is —O—C 1-6 alkyl;

the halogen is fluorine, chlorine, iodine or bromine;

R 6 , R 7 and R 8 are independent from each other and selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, or R 6 , R 7 or R 8 together with their respective connecting carbon or nitrogen atom may form a cycloalkylic or heterocyclic 4 to 7-membered ring, wherein

the aryl is phenyl, naphthyl or anthracene;

the alkyl-aryl is C 1-4 -alkyl-aryl;

the alkyl is C 1-8 alkyl;

the alkenyl is C 2-10 -alkenyl;

the alkynyl is C 2-10 -alkynyl;

the cycloalkyl is C 3-8 cycloalkyl;

and

when R 6 , R 7 or R 8 together with their respective connecting carbon or nitrogen atom form a cycloalkylic or heterocyclic ring the ring is 5 or 6 membered.

10. The compound according to claim 9 , wherein

R 1 is hydroxyl, —NR 6 R 7 , —NR 6 S(O) 2 R 7 , —NR 6 COR 7 , —NR 6 CONR 7 R 8 , —S(O) 2 R 6 , —S(O) 2 NR 6 R 7 , —CONR 6 R 7 , substituted or unsubstituted phenyl or substituted or unsubstituted imidazolyl;

R 2 is hydrogen, fluorine, CH 3 or CF 3 ;

or wherein the ring formed by R 1 and R 2 with the core structure is selected from benzoimidazole, indazole, indoline and benzothiazole, which ring may be unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, —OH, —NH 2 , —SH, ═O, —OC 1-4 alkyl unsubstituted or substituted by one or more of OH or halogen, —CN, or C 1-4 alkyl unsubstituted or substituted by one or more of OH or halogen;

R 3 is substituted or unsubstituted propyl or butyl, diethylacetamide, substituted or unsubstituted cyclopentyl or cyclohexyl, substituted or unsubstituted phenyl, or substituted or unsubstituted pyridyl, imidazolyl, indenyl, 2,3-dihydroindenyl, benzofuryl, pyrimidinyl;

R 4 is hydrogen, CH 3 or CH 2 OH;

R 5 is hydrogen or hydroxyl; and

R 6 , R 7 , and R 8 are independently from each other selected from the group consisting of hydrogen, substituted or unsubstituted methyl, ethyl, propyl or butyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyrrolidinyl, or substituted or unsubstituted benzyl, or R 6 and R 7 together with their connecting carbon atom form a cycloalkylic 5 or 6-membered ring.

11. The compound according to claim 3 , which is a compound of formula VII:

wherein

V 1 is CH or N;

m is 1 or 2;

n is 0 or 1;

R 1 is hydroxyl, —NR 6 R 7 , —NR 6 S(O) 2 R 7 , —NR 6 COR 7 , —NR 6 CONR 7 R 8 , —S(O) 2 R 6 , —S(O) 2 NR 6 R 7 , —CONR 6 R 7 , substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;

R 2 is hydrogen, halogen, or C 1-4 alkyl;

R 1 and R 2 are bonded to neighbouring atoms in the ring and together with these atoms form a saturated or unsaturated, substituted or unsubstituted ring, fused to

the—with V 1 being carbon—phenyl ring

of the core structure of formula VII

forming a double ring;

R 3 is substituted or unsubstituted alkyl, CONR 6 R 7 , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclyl;

R 4 is hydrogen or substituted or unsubstituted C 1-4 alkyl;

R 5 is hydrogen, halogen, hydroxy, substituted or unsubstituted O-alkyl, or substituted or unsubstituted alkyl;

R 6 , R 7 and R 8 are independently from each other selected from the group consisting of hydrogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkyl-aryl, or R 6 and R 7 together with their connecting carbon atom form a cycloalkylic 5 or 6-membered ring;

12. The compound according to claim 11 , wherein

R 1 is substituted or unsubstituted phenyl or substituted or unsubstituted imidazolyl;

R 2 is hydrogen, fluorine, CH 3 or CF 3 ;

R 3 is substituted or unsubstituted methyl, propyl, isopropyl, isobutyl or butyl, CONR 6 R 7 , substituted or unsubstituted cyclopentyl or cyclohexyl, substituted or unsubstituted phenyl, or substituted or unsubstituted pyridyl, imidazolyl, indenyl, indolinyl, 2,3-dihydroindenyl, benzofuryl, pyrimidinyl, quinolinyl;

R 4 is hydrogen, CH 3 or CH 2 OH;

R 5 is hydrogen or hydroxyl; and

R 6 , R 7 , and R 8 are independently from each other selected from the group consisting of hydrogen, substituted or unsubstituted methyl, ethyl, propyl isopropyl or butyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyrrolidinyl, thiazolyl or pyridyl, substituted or unsubstituted cyclopropyl or substituted or unsubstituted benzyl, or R 6 and R 7 together with their connecting carbon atom form a cycloalkylic 5 or 6-membered ring.

13. A pharmaceutical composition which comprises a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

14. A pharmaceutical composition which comprises a compound according to claim 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

15. A pharmaceutical composition which comprises a compound according to claim 3 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

16. A method of treating pain in a subject in need thereof, comprising administration of an effective amount of a compound according to claim 1 .

17. The method of claim 16 , wherein the pain is medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia or hyperalgesia.

18. A method of treating pain in a subject in need thereof, comprising administration of an effective amount of a compound according to claim 1 having a dual activity binding to the σ 1 receptor and the μ-opioid receptor.

19. A method of treating pain in a subject in need thereof, comprising administration of an effective amount of a compound according to claim 2 .

20. The method according to claim 19 , wherein the pain is medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia or hyperalgesia.

21. A method of treating pain in a subject in need thereof, comprising administration of an effective amount of a compound according to claim 3 .

22. The method according to claim 21 , wherein the pain is medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia or hyperalgesia.

23. A process for the production of a compound of formula I according to claim 1 :

wherein R 1 , R 2 , R 5 , V 1 , V 2 , V 3 , W, X, Y, Z and m are as defined in claim 1 or a compound of formula Ia

wherein R 1 , R 2 , R 3 , R 4 , R 5 , V 1 , V 2 , V 3 , W, X, Y, Z, n and m are as defined in claim 1 ,

wherein a compound of formula X or its suitable salt,

wherein R 1 , R 2 , R 5 , V 1 , V 2 , and V 3 are as defined in claim 1 , is reacted with a compound of formula XI (for a compound of formula I) or a compound of formula XIa (for a compound of formula Ia) under the conditions of Step 1

wherein R 3 , R 4 , W, X, Y, Z and n are as defined in claim 1 , leading to a compound according to formula (I) or formula (Ia) respectively,

wherein the reductive amination reaction of the compounds of formula (X) and (XI or XIa) of Step 1 is carried out with a reductive reagent in an aprotic solvent in the presence of an organic base thereby producing a compound of formula (I) as recited in claim 1 .

24. A process for the production of a compound of formula VII according to claim 11 :

wherein R 1 , R 2 , R 3 , R 4 , R 3 , n and m are as defined in claim 11 ,

wherein a compound of formula XII or its suitable salt,

wherein R 1 , R 2 , and R 5 are as defined in claim 11 , is reacted with a compound of formula XIV under the conditions of Step 2

wherein m is as defined in claim 11 , leading to a compound according to formula XIII,

wherein R 1 , R 2 , R 5 and m are as defined in claim 11 ,

followed by reacting the compound of formula XIII with a compound of formula XV under the conditions of Step 3

wherein R 3 , R 4 and n are as defined in claim 11 , under the conditions of Step 3, leading to a compound of formula (VII),

wherein X is a leaving group,

wherein the reaction of Step 2 of the compounds of formula (XII) with the compounds of formula (XIV) is carried out in the presence of a base in an aprotic solvent;

wherein the reaction of Step 3 of the compounds of formula (XIII) with the compounds of formula (XV) is carried out in the presence of a copper salt and sodium ascorbate in a mixture of protic organic solvent and water thereby producing a compound of formula VII as recited in claim 11 .

Assignments (2)

CHANGE OF NAME Recorded May 1, 2019

From: LABORATORIOS DEL DR. ESTEVE S.A.

To: ESTEVE PHARMACEUTICALS, S.A.

Reel/Frame 049837/0469 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2016

From: CUEVAS-CORDOBÉS, FÉLIX; ALMANSA-ROSALES, CARMEN; GARCIA LOPEZ, MONICA

To: LABORATORIOS DEL DR. ESTEVE S.A.

Reel/Frame 040488/0392 →

Priority Claims (1)

EP 13384004 · Dec 20, 2013 · regional

Continuity (1)

Related Publication 20170001978A1 · Jan 5, 2017